WEHI's Groundbreaking Platform Revolutionizes MS Genetic Research
Australian scientists at the Walter and Eliza Hall Institute of Medical Research (WEHI) have achieved a pivotal breakthrough in multiple sclerosis (MS) research. Led by Dr. Hamish King, the team has developed an innovative platform that enables the simultaneous study of more than 100 genetic risk factors associated with MS. This multiplexed approach marks a significant departure from traditional methods, where genetic variants were examined in isolation, offering fresh insights into how these factors interact to drive the disease.
Multiple sclerosis is a chronic autoimmune disorder where the immune system erroneously attacks the myelin sheath—the protective covering of nerve fibers in the central nervous system, including the brain and spinal cord. This damage disrupts nerve signal transmission, leading to symptoms such as fatigue, mobility issues, vision problems, cognitive challenges, and pain. The new platform tests these genetic risk factors directly in human immune cells, particularly B cells, measuring changes in gene expression and immune cell behavior both individually and collectively.
This advance addresses a longstanding challenge in MS genetics. Over the past two decades, genome-wide association studies have identified hundreds of small DNA variations linked to heightened MS risk. However, most do not directly alter protein-coding genes; instead, they influence regulatory regions that control gene activation in immune cells. Studying their combined effects has proven technically daunting until now.
Understanding Multiple Sclerosis: Prevalence and Burden in Australia
In Australia, MS affects more than 37,700 individuals as of 2025, representing a 77.4 percent increase since 2010. This rise equates to a prevalence of approximately 139.2 cases per 100,000 people, placing Australia among countries with the highest rates globally. The economic toll is staggering, exceeding $3 billion in 2024 alone, encompassing healthcare costs, lost productivity, and caregiver burdens.
Globally, around 2.8 million people live with MS, with women comprising about 75 percent of cases and onset typically between ages 20 and 40. Risk factors include genetic predisposition, Epstein-Barr virus infection, low vitamin D levels, smoking, and northern latitudes. In Australia, the southern states like Tasmania show higher incidence, possibly due to lower sunlight exposure affecting vitamin D synthesis.
The progressive nature of MS underscores the urgency: relapsing-remitting MS (RRMS) evolves into secondary progressive MS (SPMS) in many cases, leading to irreversible disability. Current disease-modifying therapies (DMTs) like ocrelizumab and natalizumab reduce relapses by 50-70 percent but fail to halt progression in advanced stages or fully repair myelin damage.
The Science Behind the WEHI Platform: A Step-by-Step Breakdown
The WEHI platform leverages advanced genomics and CRISPR-based editing to introduce MS-associated variants into primary human immune cells. Here's how it functions:
- Variant Identification: Over 200 MS-linked single nucleotide polymorphisms (SNPs) from large-scale studies like the International Multiple Sclerosis Genetics Consortium are prioritized, focusing on those in non-coding regulatory regions.
- Cell Engineering: Using CRISPR-Cas9 or base editing, precise edits mimic patient genotypes in B cells and other immune subsets sourced from healthy donors.
- Multiplexing: Up to 100+ variants are introduced combinatorially, overcoming single-variant limitations via pooled screening and barcoding.
- Functional Assays: High-throughput single-cell RNA sequencing (scRNA-seq) and ATAC-seq assess gene expression, chromatin accessibility, and immune phenotypes like proliferation, cytokine production, and autoantibody secretion.
- Network Analysis: Computational models map interactions, identifying key pathways (e.g., interferon signaling, B-cell activation) dysregulated in MS.
This integrated workflow reveals synergistic effects, such as how HLA-DRB1*15:01 (the strongest MS risk allele) amplifies others in antigen presentation pathways.
Dr. Hamish King: Leading the Charge at WEHI
Dr. Hamish King, Laboratory Head at WEHI's Gene Regulation Lab, spearheads this project. With a PhD from the University of Cambridge and undergraduate training at Flinders University, Dr. King's expertise spans genomics, bioinformatics, and immunology. His prior work includes mapping immune cell epigenomes in autoimmunity, published in high-impact journals like Science Immunology.
WEHI, nestled in Melbourne's Parkville biomedical precinct alongside the University of Melbourne, fosters deep academic ties. Dr. King holds an affiliation with the University of Melbourne's Department of Medical Biology, exemplifying how research institutes and universities collaborate to tackle complex diseases. His team, including co-investigator Dr. Viacheslav Kriachkov, benefits from WEHI's state-of-the-art facilities in single-cell sequencing and CRISPR screening.
"MS is believed to arise from many small genetic differences acting together," Dr. King notes. "This platform will connect them to specific genes and pathways they affect."
Funding and Collaborative Ecosystem Driving MS Innovation
This initiative receives $399,913 from MS Australia's 2026 grants round, part of a $2.8 million investment across four projects. Over 25 years, MS Australia has committed over $60 million to research. Additional support includes a Browne Family Postdoctoral Fellowship for Dr. James Hilton at the University of Melbourne, targeting neuroprotective compounds for progressive MS.
Australia's higher education sector plays a starring role. Other funded projects hail from the University of Queensland (sensory insoles for balance), University of Tasmania's Menzies Institute (brain blood flow), Florey Institute/University of Melbourne (virus-MS links), and Curtin University (copper-MS hypothesis). These underscore Australia's prowess in translational neuroscience.
Explore research positions advancing MS studies.
Bridging Genetic Insights to Clinical Impact
By elucidating how risk variants converge on pathways like B-cell hyperactivity and T-cell dysregulation, the platform paves the way for precision medicine. Potential outcomes include:
- Novel targets for small-molecule drugs modulating gene regulation.
- Biomarkers predicting progression or DMT response.
- Personalized risk scores integrating genetics with environment (e.g., EBV serology, vitamin D).
- Repurposed therapies, like epigenetic modifiers used in cancer.
Dr. Tennille Luker, MS Australia's Head of Research, emphasizes: "Understanding how genetic changes drive disease allows us to change its trajectory." Early validation could accelerate trials within 3-5 years.
Read the full WEHI announcement.
Australian Universities at the Forefront of MS Research
Australia punches above its weight in MS research, with world-leading groups at the University of Melbourne (WEHI/Florey), University of Sydney (Brain and Mind Centre), and Menzies Institute. The MSBase registry, hosted by Monash University, tracks over 50,000 patients globally, informing real-world evidence.
Collaborations like the Australian MS Longitudinal Study (AMSLS) integrate genetics, imaging, and clinical data. Funding from NHMRC ($50m+ since 2010) and MS Research Australia bolsters this ecosystem, training next-gen researchers via PhD/postdoc programs.
Discover university opportunities across Australia | Tips for research assistant roles.
Case study: University of Queensland's vibrotexture insoles aim to cut falls by enhancing proprioception, trialed in 100 MS patients.
Challenges and Ethical Considerations in MS Genomics
Despite promise, hurdles remain: polygenic risk scores explain only ~20-30% of MS heritability; environmental confounders like latitude and smoking complicate models. Ethical issues include genetic privacy (GDPR-like under Australia's My Health Record) and equity—ensuring therapies reach remote Indigenous communities where MS rates rise.
Dr. King's platform prioritizes diverse cell models, but scaling to patient-derived iPSCs demands resources. Long-term: Integrate with spatial transcriptomics for lesion-specific insights.
Future Horizons: From Lab to Lifeline
Over 3 years, expect pathway maps prioritizing druggable targets. Phase I trials could follow by 2030, akin to BTK inhibitors (evobrutinib) in late-stage testing. Prevention via risk stratification—e.g., high-risk EBV+ youth on antivirals—looms large.
Australia's MS momentum positions it as a global hub, attracting talent. For aspiring researchers, fields like computational immunology offer booming careers.
Postdoc openings in neuroscience.
Careers in MS Research: Opportunities Down Under
This breakthrough highlights thriving opportunities at Australian universities. Roles span wet-lab (CRISPR screening), dry-lab (bioinformatics), and clinical (trial design). WEHI/Uni Melbourne posts PhDs in genomics ($35k stipend + fees), postdocs ($90k salary), and faculty positions.
- Skills in demand: scRNA-seq, machine learning for polygenic scores.
- Entry: Honours/Masters in biotech, immunology.
- Path: PhD → postdoc → lab head/group leader.
Rate professors in medical biology | Browse higher ed jobs | Thrive as a postdoc.
Photo by David Clode on Unsplash
Conclusion: Hope on the Horizon for MS Patients
WEHI's platform heralds a new era in MS research, transforming genetic associations into actionable biology. With Australia's robust higher ed ecosystem, sustained funding, and visionary leaders like Dr. King, the path to halting—and perhaps preventing—MS grows clearer. Patients, researchers, and policymakers must unite for impact.
Explore university jobs, higher ed roles, or career advice. Share your insights in comments below.
